Influence of simvastatin at high dose and nifedipine on hemodynamic parameters in rabbits

Pharmacological Reports

Volumn 58, Issue 1, 2006, Pages 48-59

  Jasińska, Magdalena ^a   Owczarek, Jacek ^a   Orszulak Michalak, Daria ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hemodynamic parameters; Nifedipine; Rabbits; Simvastatin

Indexed keywords

CYTOCHROME P450 3A4; DOPAMINE; METHYLCELLULOSE; NIFEDIPINE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER FLOWMETRY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RABBIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

EID: 33646166127     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Abramson JJ, Buck E, Salam G, Casida JE, Pessah IN: Mechanism of antraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem, 1989, 263, 18750-18758.
2. Baker SK, Tarnopolsky MA: Statin myopathies, pathophysiologic and clinical perspectives. Clin Invest Med, 2001, 24, 258-272.
3. Catapano AL: Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J, 1997, Suppl A, A80-86.
4. De Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R: Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol, 1999, 33, 473-478.
5. Dhein S, Salameh A, Berkels R, Klaus W: Dual mode of action of dihydropyridine calcium antagonists, a role for nitric oxide. Drugs, 1999, 58, 397-404.
6. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T: Statin-stimulated nitric oxide release from endothelium. Med Sci Monit, 2001, 7, 622-627.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA, 1998, 279, 1615-1622.
8. El-Ani D, Zimlichman R: Simvastatin induces apoptosis of cultured rat cardiomyocytes. J Basic Clin Physiol Pharmacol, 2001, 12, 325-338.
9. Eliot LA, Jamali F: Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. J Pharmacol Exp Ther, 1999, 291, 188-193.
10. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease, the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial Function). Circulation, 2003, 107, 422-428.
11. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H: Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA, 1990, 87, 8931-8934.
12. Fuhrmans V: Bayer disclose higher death toll from Baycol. Wall Street Journal, 2002, A10.
13. Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, Tsujita Y. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berlin), 1993, 193, 263-273.
14. Gadbut AP, Caruso AP, Galper JB: Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol, 1995, 27, 2397-2402.
15. Gladding P, Pilmore H, Edwards C: Potentially fatal interaction between diltiazem and statins. Ann Intern Med, 2004, 140, W31.
16. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension, 1999, 34, 1281-1286.
17. Green DR, Reed JC: Mitochondria and apoptosis. Science, 1998, 281, 1309-1312.
18. Griendling KK, Alexander RW. The angiotensin (AT1) receptor. Semin Nephrol, 1993, 13, 558-566.
19. Hogan QH, Stadnicka A, Stekiel TA, Bosnjak ZJ, Kampine JP: Effects of epidural and systemic lidocaine on sympathetic activity and mesenteric circulation in rabbits. Anesthesiology, 1993, 79, 1250-1260.
20. Ichihara. K, Satoh K, Yamamoto A, Hoshi K: Are all HMG-CoA reductase inhibitors protective against ischemic heart disease? Nippon Yakurigaku Zasshi, 1999, Suppl 1, 142P-149P.
21. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension, 1997, 30, 968-974.
22. Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in atherosclerosis, a review of the potential of combination therapy. Expert Opin Pharmacother, 2004, 5, 459-468.
23. Kabas JS, Spratt JA, Davis JW, Rankin JS, Glower DD: The effects of dopamine on myocardial functional recovery after reversible ischemic injury. J Thorac Cariovasc Surg, 1990, 100, 715-723.
24. Kim DH, Landry AB 3rd, Lee YS, Katz AM: Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum, vesicles. J Mol Cell Cardiol, 1989, 21, 433-436.
25. Klip A, Hill M, Ramlal T: Halothane increases cytosolic Ca2+ and inhibits Na+/H+ exchange in L6 muscle cells. J Pharmacol Exp Ther, 1990, 254, 552-559.
26. Kong JY, Rabkin SW: Lovastatin does not accentuate but is rather additive to palmitate-induced apoptosis in cardiomyocytes. Prostaglandins Leukot Essent Fatty Acids, 2002, 67, 293-302.
27. Levasseur J, Kontos HA: Effects of anesthesia on cerebral arteriolar responses to hypercapnia. Am J Physiol, 1989, 257, H85-88.
28. Ma B, Prueksaritanont T, Lin JH: Drug interactions with calcium channel blockers, possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos, 2000, 28, 125-130.
29. Marumo, H, Satoh K, Yamamoto A, Kaneta S, Ichihara K: Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku Zasshi, 2001, 121, 761-764.
30. Marz W, Siekmeier R, Muller EM, Wieland H, Gross W, Olbrich HG: Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther, 2000, 5, 275-279.
31. Matzno S, Yamauchi T, Gohda M, Ishida N, Katsuura K, Hanasaki Y, Tokunaga T et al.: Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res, 1997, 38, 1639-1648.
32. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P: Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther, 2000, 68, 391-400.
33. Mital S, Zhang X, Zhao G, Bernstein RD, Smith CJ, Fulton DL, Sessa WC et al.: Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol, 2000, 279, H2649-2657.
34. Miyake Y, Shouzu A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S, Hayakawa T et al.: Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung, 1999, 49, 324-329.
35. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J, Higuchi I et al.: Myopathy induced by HMG-CoA reductase inhibitors in rabbits, a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol, 1998, 152, 99-106.
36. Nakahara K, Kuriyama M, Yoshidome H, Nagata K, Nagado T, Nakagawa M, Arimura K et al.: Experimental simvastatin-induced myopathy in rabbits. J Neurol Sci, 1992, 113, 114-117.
37. Nakahara K, Yada T, Kuriyama M, Osame M: Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res, Commun, 1994, 202, 1579-1585.
38. Nakamura T, Okada K, Nagata K, Yamazoe Y: Intestinal cytochrome P450 and response to rifampicin in rabbits. Jpn J Pharmacol, 2000, 82, 232-239.
39. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, Dal Bello B et al.: Apoptosis in heart failure, release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA, 1999, 96, 8144-8149.
40. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation, 1999, 100, 2131-2134.
41. Nievelstein HM, Van Essen H, Tijssen CM, Smits JF, Struyker Boudier HA: Systemic and regional hemodynamic actions of calcium entry blockers in conscious spontaneously hypertensive rats. Eur J Pharmacol, 1985, 113, 187-198.
42. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension, 1992, 20, 651-658.
43. Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother, 2001, 35, 1096-1107.
44. Opie LH: Pharmacological differences between calcium antagonists. Eur Heart J, 1997, Suppl A, A71-79.
45. Park JK, Kim SZ, Kim SH, Kim. YG, Cho KW: Renin angiotensin system of rabbit clitoral cavernosum, interaction with nitric oxide. J Urol, 2000, 164, 556-561.
46. Patterson D, Dick JB, Struthers AD: Intensive statin treatment improves baroreflex sensitivity, another cardioprotective mechanism for statins? Heart, 2002, 88, 415-416.
47. Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils C, Thenot JP, Maurel P: Identification of the rabbit and human cytochromes P-450 IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos, 1990, 18, 711-719.
48. Pierno S, De Luca A, Liantonio A, Camerino C, Conte Camerino D: Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur J Pharmacol, 1999, 364, 43-48.
49. Pliquett RU, Cornish KG, Zucker IH: Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation, 2003, 107, 2493-2498.
50. Pliquett RU, Cornish KG, Zucker IH: Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol, 2003, 95, 700-704.
51. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339, 1349-1357.
52. Rabkin SW, Kong JY: Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol Appl Pharmacol, 2003, 193, 346-355.
53. Rabkin SW: Lovastatin induces cell death in cardiomyocytes that is not reversible by coenzyine Q 10. Pharmacol Toxicol, 2002, 90, 343-345.
54. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
55. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med, 1996, 335, 1001-1009.
56. Satoh K, Ichihara K: Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol, 2000, 35, 256-262.
57. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE: Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet, 1998, 27, 1929-1930.
58. Scholz H: Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther, 1997, Suppl. 3, 869-872.
59. Shepherd J: A tale of two trials, The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study. Atherosclerosis, 1998, 139, 223-229.
60. Sinko PJ, Kunta JR, Usansky HH, Perry BA: Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther, 2004, 310, 359-366.
61. Smits JF, Struyker-Boudier HA: The mechanisms of antihypertensive action of beta-adrenergic receptor blocking drugs. Clin Exp Hypertens A, 1982, 4, 71-86.
62. Stepień K, Tomaszewski M, Czuczwar S: Neuroprotective properties of statins. Pharm Rep, 2005, 57, 561-569.
63. Struyker-Boudier HA, Nievelstein HM, van Essen H, Smits JF: Calcium antagonists, systemic and regional hemodynamic effects in conscious spontaneously hypertensive rats (SHR). J Hypertens Suppl, 1984, 2, S527-529.
64. Ucar M, Mjorndal T, Dahlqvist R: HMG-CoA reductase inhibitors and myotoxicity. Drug Saf, 2000, 22, 441-457.
65. Vaidya S, Walwaikar P, Kadhe G: Evaluation of anti-atherosclerotic and vasculoprotective effect of long acting nifedipine in patients after PTCA. J Indian Med Assoc, 2001, 99, 519-20, 522.
66. van Woerkens LJ, van der Giessen WJ, Verdouw PD: Cardiovascular effects of dopamine and dobutamine in conscious pigs with chronic heart failure. Crit Care Med, 1993, 21, 420-424.
67. van Zwieten PA: Receptor-mediated inotropic drugs. Eur Heart J, 1988, Suppl H, 85-90.
68. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G et al.: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001, 37, 1450-1457.
69. Wilson TW, Alonso-Galicia M, Roman RJ: Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension, 1998, 31, 225-231.
70. Yamashita T, Kawashima S, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N et al.: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens, 2002, 20, 2465-2473.
71. Yaoita H. Ogawa K, Maehara K, Maruyama Y: Attenuation of ischemia/ reperfusion injury in rats by a caspase inhibitor. Circulation, 1998, 97, 276-281.
72. Yeung PK, Mosher SJ, Pollak PT: Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration. Eur J Drug Metab Pharmacokinet, 1991, 16, 69-74.
73. Yoshida M, Ueda S, Machida J: Effects of nifedipine on renal cortical and medullary blood in two-kidney, one clip renovascular hypertension in rabbits. Urol Int, 1990, 45, 284-289.
74. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H et al.: Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease, the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res, 2004, 27, 181-191.
75. Zeitz O, Maass AE, Van Nguyen P, Hensmann G, Kogler H, Moller K, Hasenfuss G et al.: Hydroxyl radical-induced acute diastolic dysfunction is due to calcium overload via reverse-mode Na(+)-Ca(2+) exchange. Circ Res, 2002, 90, 988-995.
76. Zhao R, Fennel WH, Abel FL: Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics. Eur J Pharmacol, 1990, 190, 193-202.